Category Archives: Cell Biology

Out of Deep-Sea Mud, a Strange Blob May Hold Secrets to the Origins of Complex Life – Livescience.com

A microbe found in the muddy depths of the Pacific Ocean doesn't look like much other than a blob with tentacles. But this unassuming little organism may hold the secrets to how the first multicellular life-forms evolved, according to new research.

Long before complex organisms existed, the world was home to simple single-celled organisms, archaea and bacteria. Between 2 billion and 1.8 billion years ago, these microorganisms began to evolve, leading to the emergence of more complex life-forms called eukaryotes, a group that includes humans, animals, plants and fungi. But this incredible journey over which life transitioned from swimming blobs to walking (and, in some cases, thinking and feeling) animals is still poorly understood.

Scientists had previously hypothesized that a group of microbes called Asgard archaea were the much-sought ancestors of eukaryotes, because they contain similar genes to their complex counterparts, according to a statement. To analyze what these microbes looked like and how this transition might have happened, a group of researchers in Japan spent a decade collecting and analyzing mud from the bottom of the Omine Ridge off the coast of Japan.

Related: Earth's Oldest Living Things Immortalized in Stunning Photos

The team kept the mud samples and the microorganisms in them in a special bioreactor in the lab that mimicked conditions of the deep sea in which they were found. Years later, they began to isolate the microorganisms within the samples. The scientists' initial purpose was to find microbes that eat methane and that might be able to clean up sewage, according to the New York Times. But when they discovered that their samples contained a previously unknown strain of Asgard archaea, they decided to analyze it and grow it in the lab.

They named the newly found strain of Asgard archaea Prometheoarchaeum syntrophicum after the Greek god Prometheus, who is said to have created humans from mud. They found that these archaea were relatively slow growers, only doubling in number every 14 to 25 days.

Their analysis confirmed that P. syntrophicum had a great number of genes that resembled those of eukaryotes. Indeed, these genes held the instructions for creating certain proteins found inside these microbes; but the proteins did not, as expected, create any organelle-like structures like the ones found inside eukaryotes.

They also found that the microbes had long, branching tentacle-like protrusions on their outside that might be used to snatch up passerby bacteria. Indeed, the team found that the microbes tended to stick onto other bacteria in the lab dishes.

The authors propose a hypothesis for what went on in these ancient waters: Around 2.7 billion years ago, oxygen began to accumulate on our planet. But having lived in a world without oxygen for so long, this element would prove toxic to P. syntrophicum, the authors explained in a video.

So the P. syntrophicum may have developed a new adaptation: a way to form partnerships with bacteria that were oxygen-tolerant. These bacteria would give P. syntrophicum the necessary vitamins and compounds to live, while, in turn, feeding on the archaea's waste.

As oxygen levels increased even further, P. syntrophicum might have become more aggressive, snatching passerby bacteria with its long tentacle-like structures and internalizing it. Inside the P. syntrophicum, this bacteria might have eventually evolved into an energy-producing organelle key to eukaryote-survival: the mitochondria.

The team's "success in culturing Prometheoarchaeum after efforts spanning more than a decade represents a huge breakthrough for microbiology," Christa Schleper and Filipa L. Sousa, both researchers at the University of Vienna who were not involved in the study, wrote in an accompanying editorial in the journal Nature. "It sets the stage for the use of molecular and imaging techniques to further elucidate the metabolism of Prometheoarchaeum and the role of [eukaryotic signature proteins] in archaeal cell biology."

The findings were published Jan. 15 in the journal Nature.

Originally published on Live Science.

View original post here:
Out of Deep-Sea Mud, a Strange Blob May Hold Secrets to the Origins of Complex Life - Livescience.com

Hackensack Meridian Health Center for Discovery and Innovation to Host Genomic Medicine Symposium – P&T Community

NUTLEY, N.J., Jan. 17, 2020 /PRNewswire/ --Genomic medicine's groundbreaking treatments, and its future promise, will be the focus of a full-day symposium at the Hackensack Meridian Health Center for Discovery and Innovation (CDI) on Wednesday, February 19.

This emerging discipline for tailoring active clinical care and disease prevention to individual patients will be the focus of presentations given by eight experts from medical centers in the U.S.A. and Canada.

"The Genomic Medicine Symposium convenes a diverse group of scientific experts who help serve as a vanguard for precision medicine," said David Perlin, Ph.D., chief scientific officer and vice president of the CDI. "At the Center for Discovery and Innovation, we are working to make genomics a central component of clinical care, and we are delighted to host our peers and partners from other institutions."

"The event is one-of-a-kind," said Benjamin Tycko, M.D., Ph.D., a member of the CDI working in this area, and one of the hosts. "We are bringing together great minds with the hope it will help inform our planning for genomic medicine within Hackensack Meridian Health and inspire further clinical and scientific breakthroughs."

Cancer treatments, neuropsychiatric and behavioral disorders, cardiometabolic conditions, autoimmune disease, infectious disease, and a wide array of pediatric conditions are areas where DNA-based strategies of this type are already employed, and new ones are being tested and refined continually.

The speakers come from diverse medical institutions and will talk about a variety of clinical disorders in which prevention, screening, and treatment can be informed through genomic and epigenomic data.

Among the speakers are: Daniel Auclair, Ph.D., the scientific vice president of the Multiple Myeloma Research Foundation; Joel Gelernter, M.D., Ph.D., Foundations Fund Professor of Psychiatry and Professor of Genetics and of Neuroscience and Director, Division of Human Genetics (Psychiatry) at Yale University; James Knowles, M.D., Ph.D., professor and chair of Cell Biology at SUNY Downstate Medical Center in Brooklyn; Tom Maniatis, Ph.D., the Isidore S. Edelman Professor of Biochemistry and Molecular Biophysics, director of the Columbia Precision Medicine Initiative, and the chief executive officer of the New York Genome Center; Bekim Sadikovic, Ph.D., associate professor and head of the Molecular Diagnostic Division of Pathology and Laboratory Medicine at Western University in Ontario; Helio Pedro, M.D., the section chief of the Center for Genetic and Genomic Medicine at Hackensack University Medical Center; Kevin White, Ph.D., the chief scientific officer of Chicago-based TEMPUS Genetics; and Jean-Pierre Issa, M.D., Ph.D., chief executive officer of the Coriell Research Institute.

The event is complimentary, but registration is required. It will be held from 8 a.m. to 4:30 p.m. at the auditorium of the CDI, located at 111 Ideation Way, Nutley, N.J.

The event counts for continuing medical education (CME) credits, since Hackensack University Medical Center is accredited by the Medical Society of New Jersey to provide continuing medical education for physicians.

Hackensack University Medical Center additionally designates this live activity for a maximum of 7 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information, visit https://www.hackensackmeridianhealth.org/CDIsymposium.

ABOUTHACKENSACKMERIDIAN HEALTH

Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.

Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two children's hospitals - Joseph M. Sanzari Children's Hospital in Hackensack, K. Hovnanian Children's Hospital in Neptune; nine community hospitals Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital Carrier Clinic in Belle Mead; and two rehabilitation hospitals - JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick.

Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 34,100 team members, and 6,500 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.

The network's notable distinctions include having four hospitals among the top 10 in New Jersey by U.S. News and World Report. Other honors include consistently achieving Magnet recognition for nursing excellence from the American Nurses Credentialing Center and being named to Becker's Healthcare's "150 Top Places to Work in Healthcare/2019" list.

The Hackensack Meridian School of Medicine at Seton Hall University, the first private medical school in New Jersey in more than 50 years, welcomed its first class of students in 2018 to its On3 campus in Nutley and Clifton. Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer care when and where they need it.

Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.

For additional information, please visit http://www.HackensackMeridianHealth.org.

About the Center for Discovery and Innovation:

The Center for Discovery and Innovation, a newly established member of Hackensack Meridian Health, seeks to translate current innovations in science to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions. The CDI, housed in a fully renovated state-of-the-art facility, offers world-class researchers a support infrastructure and culture of discovery that promotes science innovation and rapid translation to the clinic.

View original content to download multimedia:http://www.prnewswire.com/news-releases/hackensack-meridian-health-center-for-discovery-and-innovation-to-host-genomic-medicine-symposium-300989060.html

SOURCE Hackensack Meridian Health

See more here:
Hackensack Meridian Health Center for Discovery and Innovation to Host Genomic Medicine Symposium - P&T Community

Regenerative Medicine Market 2026: Product Approvals and Growing Pipeline of Regenerative Medicine P – PharmiWeb.com

Future Trends, Drivers & Opportunity: Rising Demand for Organ Transplantation, Implementation of the 21st Century Cures Act, Rising Government Investments in Regenerative Medicine Research, Rising Prevalence of Chronic Diseases and Genetic Disorders

Regenerative Medicine Market Analysis:

Global Regenerative Medicine Market was valued at USD 19.10 Billion in 2018 and is expected to witness a growth of 22.72% from 2019-2026 and reach USD 98.10 Billion by 2026.

Get PDF Sample Brochure @ https://decisionmarketreports.com/request-sample/1049915

What is Regenerative Medicine Market?

The field of regenerative medicine comprises of abundant strategies, which mainly includes use of materials and de novo generated cells, as well as various amalgamations thereof, to substitute the lost tissue, efficiently replacing it both anatomically and functionally, or to contribute to tissue restoration. The main objective of regenerative medicine is to propagate replacement tissue or organs for patients who have sustained an injury or have had a disease that permanently damaged their tissue. National Institutes of Health defines regenerative medicine as a process of creating living, functional tissues to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects.

Regenerative Medicine can be perceived as an interdisciplinary field of research and clinical applications which mainly focuses on the repair, replacement or regeneration of cells, tissues or organs. Regenerative Medicine mainly restores impaired function resulting from any cause. Regenerative medicine has the ability to rectify or substitute tissues and organs impaired by age, disease, or trauma, as well as to normalize congenital defects.

Know More About Research Methodology https://decisionmarketreports.com/request-methodolgy/1049915

Regenerative Medicine Market Outlook

Over the last decade, stem cell biology has experienced a breakthrough in scientific and technological developments that will together have foremost and continuing influence on regenerative medicine. These entails capability to produce pluripotent stem cells from adult body cells and to cultivate mini-organs from these or from adult stem cells in well-defined culture conditions. Both methodologies offer ways to develop functional cells of human tissue that could be used for transplantation and tissue repair.

Government policies favoring regenerative medicine is one of the major reasons which has been driving the market growth. The European Union (EU) and Dutch government have prioritized regenerative medicine as an area of key strategic relevance. Apart from this, rapid increase in aged population has also boomed the market in North American region. The North Carolina Tissue Engineering and Regenerative Medicine Society is an organization in the U.S. working to improve and advance basic research, commercial development and education in the field of regenerative medicine. In the U.S., two major government agencies NIH and CIRM gather funds for academic translational stem cell research and regenerative medicine development. Increasing global healthcare expenditure is also expected to fuel the market.

Lack of awareness and ethical issues regarding the use of Embryonic Stem Cell for R&D is expected to hinder the market for regenerative medicine. The market growth rate is highly influenced by the adoption rate of cell therapy in the market, as it is an integral part of regenerative medicine. After conducting a survey, following statistics were fetched in terms of major hindrances in stem cell research.

A survey was conducted and the respondents had above rating on a scale of 1-5, where 1 stands for not limiting and 5 stands for major limitation. Respondents rated Expense as the most limiting hindrance in stem cell research. Thus, high cost of investment could be one of the major restraints of the market followed by issues of assay sensitivity, robustness and reproducibility; difficulty of culture/propagation; and then difficulty of handling.

Global Regenerative Medicine Market Segmentation

The Global Regenerative Medicine Market is classified on the basis of Therapy, Product, Application and Region. The gist of breaking down the market into various segments is to gather the information about various aspects of the market. On the basis of Therapy, the market is bifurcated on the basis of Cell Therapy, Immunotherapy, Tissue Engineering, and Gene Therapy. The Cell Therapy is expected to be dominating in the market. The reason for this could be growing stem cell research and development.

In terms of Product, the market study encompasses various aspects such cell-based products and acellular products. Growing funding for new stem cell lines is boosting the growth of cell-based products in the global market. With growing R&D work occurring in Asian countries, the Asia Pacific region will grow at the fastest pace. Another reason for the growth rate could be rising awareness and establishments of bio-banks/stem cell banks.

Regenerative Medicine Market Competitive Landscape

The Regenerative Medicine Market study report offers a valuable insight with an emphasis on global market including some of the major players such as Organogenesis Inc., Osiris Therapeutics, Inc., Vericel Corporation, Stryker Corporation and NuVasive, Inc. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above mentioned players globally.

Analyst View:

Since tissue engineering and regenerative medicine arose as an industry about two decades ago, a wide range of therapies have received Food and Drug Administration (FDA) authorization of commercial availability. Advent of stem cells have boomed the market for regenerative medicine. Geopolitical policies have increased the scope for regenerative medicine.

The case of Japan justifies the attention it has been getting lately. The Japans initiative that included the reform of law based on regenerative medicine is attracting business toward the country. The creation of the Forum for Innovative Regenerative Medicine (FIRM) in 2014, comprising 185 firms as of January 2016, and the participation of an increasing number of organizations from the United States, Canada, the United Kingdom, Sweden, and Australia, represented a significant breakthrough.

The field of regenerative medicine is expected to provide new opportunities bring numerous opportunities across. Various key industry players have come ahead to invest in regenerative medicine. The concept of regenerative medicine is actively being implemented in across various applications such as Oncology, Cardiology, Orthopedic & Musculoskeletal Disorders, etc.

About Us

Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

Contact Us

Gasper James

304, S Jones Blvd,

Las Vegas,

NV 89107, USA

US Toll Free +18666051052

Email: sales@decisionmarketreports.com

Web: http://decisionmarketreports.com/

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

More:
Regenerative Medicine Market 2026: Product Approvals and Growing Pipeline of Regenerative Medicine P - PharmiWeb.com

Correlative three-dimensional super-resolution and block-face electron microscopy of whole vitreously frozen cells – Science Magazine

David P. Hoffman

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Gleb Shtengel

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

C. Shan Xu

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Kirby R. Campbell

Department of Developmental Neurobiology, St. Jude Childrens Research Hospital, Memphis, TN 38105, USA.

Melanie Freeman

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Lei Wang

Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.Program in Cellular and Molecular Medicine, Boston Childrens Hospital, Boston, MA 02115, USA.Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

Daniel E. Milkie

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

H. Amalia Pasolli

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Nirmala Iyer

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

John A. Bogovic

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Daniel R. Stabley

Neuroimaging Laboratory, St. Jude Childrens Research Hospital, Memphis, TN 38105, USA.

Abbas Shirinifard

Bioimage Analysis Core, St. Jude Childrens Research Hospital, Memphis, TN 38105, USA.

Song Pang

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

David Peale

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Kathy Schaefer

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Wim Pomp

Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.Program in Cellular and Molecular Medicine, Boston Childrens Hospital, Boston, MA 02115, USA.Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

Chi-Lun Chang

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Jennifer Lippincott-Schwartz

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Tom Kirchhausen

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.Program in Cellular and Molecular Medicine, Boston Childrens Hospital, Boston, MA 02115, USA.Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

David J. Solecki

Department of Developmental Neurobiology, St. Jude Childrens Research Hospital, Memphis, TN 38105, USA.

Eric Betzig

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA.Department of Physics, University of California, Berkeley, CA 94720, USA.Howard Hughes Medical Institute, Berkeley, CA 94720, USA.Helen Wills Neuroscience Institute, Berkeley, CA 94720, USA.Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.

Harald F. Hess

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Read more:
Correlative three-dimensional super-resolution and block-face electron microscopy of whole vitreously frozen cells - Science Magazine

Good night’s sleep has power to turn back clock, and study could ‘unlock mysteries of ageing’ – inews

NewsScienceNow, academics have explained for the first time the mystery of why it is so replenishing to be out like a light

Wednesday, 15th January 2020, 9:39 pm

Biologists at the University of Manchester have studied mice to show how the diurnal rhythm, or body clock, can boost the ability to maintain important cell structures during the day. It is hoped the study could one day help unlock some of the mysteries of ageing.

Professor Karl Kadler, lead author of a report published in Nature Cell Biology, said: Knowing this could have implications on understanding our biology at its most fundamental level. It might give us some deeper insight into how wounds heal, or how we age.

Turning back the clock

The universitys discovery throws a light on the bodys extracellular matrix, which provides structural and biochemical support to cells in the form of connective tissue such as bone, skin, tendon and cartilage.

The researchers have discovered the body has two types of fibrils rope-like structures of collagen that are woven by the cells to form tissues.

Thicker fibrils are permanent and stay with us throughout our lives, unchanged from the age of 17. But thinner fibrils break as the body is subjected to the rigours of the day and replenishing when we get a good rest at night.

Its intuitive to think our matrix should be worn down by wear and tear, but it isnt and now we know why. Our body clock makes an element which can be replenished, Professor Kadler said.

Sleep patterns

Researchers at the same university found last year that blue light might not be as disruptive to sleep patterns as previously thought and using cooler lighting in the evening and bright warmer lights in the day may be more beneficial.

Collagen provides the body with structure and is our most abundant protein, ensuring the integrity, elasticity and strength of the bodys connective tissue, Professor Kadler said.

Its intuitive to think our matrix should be worn down by wear and tear, but it isnt and now we know why. Our body clock makes an element which can be replenished.

Go here to read the rest:
Good night's sleep has power to turn back clock, and study could 'unlock mysteries of ageing' - inews

Why stem cells could be the medical innovation of the century – World Economic Forum

Right now, your bodys stem cells are working hard replacing your skin every two weeks, creating new red and white blood cells and completing thousands of other tasks essential to life. They are your own personalized fountain of youth.

Scientists generally agree that a stem cell should be able to do both of the following:

One theory of ageing suggests that between the ages of 30 and 50, our stem cells reach a turning point and start to decline in number and function. This results in the typical features associated with ageing.

There does not seem to be a single discoverer of stem cells. Accounts date back to the 1800s and even further, but the first successful medical procedure was a bone marrow transfusion in 1939. Advances in immunology led to donor matching, initially via siblings and close relatives. Unrelated donor matching flourished in the 1970s, alongside donor registries.

In the 1980s, scientists identified embryonic stem cells in mice, leading to the 1997 cloning of Dolly the Sheep. This created immense interest for human and medical applications and a backlash in the US as federal R&D funding was essentially halted in 2001.

In 2012, a Nobel Prize was awarded for the earlier discovery of induced pluripotent stem cells (iPS). Essentially, they return potency and self-renewal properties to mature non-stem cells, essentially making them act like stem cells again.

In the decade between 2010 and 2019, the first wave of stem cell start-ups emerged, alongside R&D programmes at many large pharmaceutical companies, leading to innovation and the first human clinical trials for iPS and other related therapies.

According to Q3 2019 data from the Alliance for Regenerative Medicine, there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials; 525 of these companies are in North America, 233 in Europe and Israel, and 166 in Asia. In aggregate, $7.4 billion has been invested in regenerative medicine companies in 2019; $5.6 billion of which has been dedicated to gene and gene-modified cell therapy, $3.3 billion in cell therapy, and $114 million in tissue engineering.

Overview of the cancer stem cells market

Perhaps most excitingly, curative therapies are hitting the market and the results are astonishing: 60% of Acute Lymphoblastic Leukemia patients taking Novartis Kymirah showed a complete response (no traces of cancer) and were declared in full remission. Meanwhile, 75% of patients with Transfusion-Dependent -Thalassaemia treated with bluebird bios Zynteglo achieved independence from transfusions. Perhaps most astonishingly, 93% of spinal muscular atrophy patients treated with Novartis Zolgensma were alive without permanent ventilation 24 months after treatment. We should expect more medical breakthroughs in the coming years.

New science, new start-ups: several companies in the sector have gone public or been acquired. These exits led to the recycling of talent and capital into new companies. Because the science and commercial systems have also advanced, the companies in the next wave are pursuing bigger challenges, driving innovation, with even greater resources.

Patients are eager: the current market for stem cell therapies is growing at 36% per year, though it will rapidly expand when a breakthrough occurs toward the treatment of a non-communicable disease (such as cancer, diabetes, heart disease) or a lifestyle factor (for example, growing hair in the correct places, expanding cognitive abilities or increasing healthy lifespan).

New R&D models: funding is flowing into the sector from large companies, VC funds, and institutions such as the California Institute for Regenerative Medicine (CIRM) and New York State Stem Cell Science programme (NYSTEM). Some of the leading university R&D platforms include the Center for the Commercialization of Regenerative Medicine in Toronto, the Stanford Institute for Stem Cell Biology and Regenerative Medicine, the Oxford Stem Cell Institute, and most notably, the Harvard Stem Cell Institute (HSCI).

Founded in 2004, HSCI has established a phenomenal track record. It provided the first $200,000 in funding to Derrick Rossis lab, which inspired the largest biotech IPO to date. HSCI scientists were also co-founders or principals in the three most prominent gene-editing companies (CRISPR Tx, Intellia and Editas), the combined $1.55-billion True North/iPierian acquisitions and the recent $950-million acquisition of Semma Tx, Frequency Tx, Fate Tx, Epizyme Inc., and Magenta Tx.

For the casual investor, Evercore ISI is building a Regenerative Medicine Index, which may be the simplest way to build a portfolio. For institutions and those with deeper pockets, regenerative medicine funds are forming, including the Boston-centric Hexagon Regenerative Medicine Fund, which aims to create companies out of the Harvard Stem Cell Institute.

Caveat emptor. Though patients needs are immediate, those seeking treatments should think very carefully about the risks. There are many dubious clinics touting expensive stem cell treatments and some patients have experienced horrifying complications. Dr. Paul Knoepfler of UC-Davis has written a practical and scientifically accurate guide, a strongly recommended read if you or a family member are considering treatment or a clinical trial.

The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.

Total disease burden by disease or injury

Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimers disease and diabetes). Based on the early promise mentioned above, regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

See original here:
Why stem cells could be the medical innovation of the century - World Economic Forum

Aberdeenshire schools urged to get creative and light the north – Buchan Observer

Schools and community youth groups are being asked to get involved with a creative north-east sculpture and education programme.

The leading cancer support and wellbeing charity, CLAN Cancer Support, is looking for young people to get involved with the Little Lights Education programme, which will run alongside the Light the North lighthouse trail.

The trail will take place in Autumn 2020 and will see 8 ft high decorated lighthouses and mini lighthouse sculptures across Aberdeen and Aberdeenshire, Moray, Orkney and Shetland.

The Little Lights Education Programme links to the Curriculum for Excellence with all participating schools and community groups being provided with a creative learning resource pack.

The pack contains a programme of study designed to complement teaching of numerous subjects including the history and development of lighthouses, a link to the sea including renewables and wider energy sector, maritime, cell biology, physical health and emotional wellbeing with a focus on the development of personal resilience.

Iona Mitchell, CLANs head of cancer support services, said: Numerous schools and community youth groups have noted their interest in the Little Lights programme, and we are encouraging more to take part, before the final deadline on January 31.

The education programme is fascinating as it gives a real insight into the lighthouses of the north-east and our relationship with the sea. Furthermore, the pack contains age-appropriate information about cancer. A diagnosis of cancer, in a family, can have a significant impact on a childs emotional wellbeing.

"The Little Lights Education Programme aims to empower our future adults to manage their physical and emotional wellbeing and develop personal resilience which will provide them with lifelong strategies to employ, which will help them navigate through difficult times.

After getting creative in the classroom, teachers, parents and young people will see their 3D masterpiece on the art trail alongside those of contemporary artists at museums, libraries, galleries and leisure venues. After 10 weeks on public display, each little lighthouse sculpture will go back to the school or community to keep.

We urge schools and communities to be part of this unique event that will raise vital funds for CLAN Cancer Support and deliver significant benefits to teachers, pupils, and our community.

The deadline for schools taking part in the programme is January 31. To take part schools and community groups should visit http://www.lightthenorth.co.uk where they can download an education pack.

More here:
Aberdeenshire schools urged to get creative and light the north - Buchan Observer

Special delivery: McMaster physicists design super-human red blood cells to deliver drugs to specific targets within the body – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Newswise A team of physicists from McMaster University has developed a process to modify red blood cells so they can be used to distribute drugs throughout the body, which could specifically target infections or treat catastrophic diseases such as cancer or Alzheimers.

The modified red blood cells are designed to circulate in the body for several weeks at a time, seeking out specific targets including bacteria, tumours or organs.

The technology, described in the online edition of the journal Advanced Biosystems, solves a major problem with current drug delivery methods that use synthetic molecules and cannot reach specific targets or are rejected by the body.

We call these super-human red blood cells. We think that they could work as the perfect stealth drug carriers which can outsmart our immune system, explains Maikel Rheinstdter, a senior advisor on the study and professor in the Department of Physics & Astronomy at McMaster.

The researchers have developed a method to open up the red blood cell, modify its outer cell wall, and replace its contents with a drug molecule, which would then be injected back into the body.

The hybrid appears and behaves as a normal red blood cell, but has a sticky surface which can attach itself to bacteria, for example, open up and release antibiotics exactly where they are needed.

We have combined synthetic material with biological material and created a new structure, which has never been done before in this way, says Sebastian Himbert, lead author and a graduate student in the Department of Physics & Astronomy at McMaster.

The entire process is very efficient and can be completed in one day in the lab, he says.

Researchers believe this targeted delivery method could help to minimize dosages and therefore, potential side effects. This is particularly important for very potent drugs used in cancer and Alzheimers disease, and the treatment of infections of potentially resistant bacteria.

The work was done in collaboration with Harald Stver, professor in the Department of Chemistry and Chemical Biology at McMaster, Janos Juhasz from the Juravinski Cancer Centre, and researchers at Saarland University in Germany.

A high res photo and video of researchers Maikel Rheinstdter and Sebastien Himbert can be found at this link: https://assets.adobe.com/public/907bc03f-19a0-4454-6dda-d1d10a57eb0a

Attention editors: A copy of the study can be found at the link below:

Adv. Biosys.2020, 1900185 Hybrid erythrocyte liposomes: functionalized red blood cell membranes for molecule encapsulation, Sebastian Himbert, Matthew J. Blacker, Alexander Kihm, Quinn Pauli, Adree Khondker, Kevin Yang, Sheilan Sinjari, Mitchell Johnson, Janos Juhasz, Christian Wagner, Harald D. H. Stver and Maikel C. Rheinstdter

Adv. Biosys.2020, 1900185

https://doi.org/10.1002/adbi.201900185

SEE ORIGINAL STUDY

Go here to see the original:
Special delivery: McMaster physicists design super-human red blood cells to deliver drugs to specific targets within the body - Newswise

Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products | More News |…

DetailsCategory: More NewsPublished on Wednesday, 15 January 2020 15:24Hits: 501

Multi-target collaboration combines Artisan Bio's proprietary synthetic biology platform with Takeda's Cell Therapy Expertise

DENVER, CO, USA I January 15, 2020 I Artisan Bio, Inc., a stealth cell therapy engineering company, today announced it has entered into a global research and collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") for the discovery, development, and commercialization of novel cell therapy products.

Under the terms of the agreement, Artisan Bio will deploy its STAR platform and synthetic biology expertise to construct customized and precisely engineered cell therapies. Artisan will lead discovery efforts, including gene editing, and Takeda will be responsible for the development, manufacturing, and commercialization of the resulting cell therapy products.

"We are thrilled to collaborate with Takeda and combine our advanced cell engineering capabilities with Takeda's visionary cellular therapy programs," said Ryan T. Gill, CEO of Artisan Bio. "Many limitations that exist in current generation cell therapies can be addressed through the precision engineering of cells for enhanced performance. This collaboration will accelerate the availability of more effective next-generation cellular therapies for patients with high unmet needs."

About Artisan Bio:Artisan's vision is to design, build, and deliver cells and precision engineering processes thatadvance cellular therapies across a broad range of human health indications. The company's designer cell engineering and data analysisSTARplatform enables partners to more rapidly and cost effectively generate safer and more efficacious cell therapies. By engaging in strategic collaborations with innovativepartners, Artisan seeks to deliver customizable cellengineering solutions that meet the complexitiesassociatedwith next-generation cell therapies. Artisan has offices in Denver, Colorado and Copenhagen, Denmark.

For more information, please visithttp://artisancells.com/.

SOURCE: Artisan Bio

Read the original:
Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products | More News |...